WO2000004132A1

WO2000004132A1 - Mass production method of lactoferrin polypeptide from yeast and useful microorganism thereof

Info

Publication number: WO2000004132A1
Application number: PCT/KR1999/000373
Authority: WO
Inventors: Chang Keun Sung; In Sun Joo; Moon Sook Woo; Sang Kyu Kim; Jeong Hyun Lee; Keum Soon Lee; Young Ho Kim; Seung Suh Hong; Hyun-Soo Lee
Original assignee: Samyang Genex Corporation
Priority date: 1998-07-15
Filing date: 1999-07-14
Publication date: 2000-01-27
Also published as: AU4656999A

Abstract

The present invention relates to a method of mass-producing lactoferrin polypeptide from yeast which is resistant to lactoferrin polypeptide. The present invention also provides Pichia strains, especially Pichia pastoris KCTC 0500BP that are resistant to lactoferrin polypeptide.

Description

MASS PRODUCTION METHOD OF LACTOFERRIN POLYPEPTIDE FROM YEAST AND USEFUL MICROORGANISM THEREOF

TECHNICAL FIELD AND BACKGROUND ART

Lactoferrin is a glycoprotein that has physiological and biological characteristics such as bactericidal, growth stimulatory, iron carrying activity, immune modulation, and specific reaction to membrane receptors.

The structure of human lactoferrin is composed of 681 amino acid residues. There is an iron-binding site in between the domains of one of the two lobes. Lactoferrin is known to have immuno-stimulatory effect and antibacterial activity. Also, it is reported that the peptides or polypeptides derived from lactoferrin are superior to lactoferrin itself in antibacterial activity and stability (US patent 5304633; 5571697). Therefore, lactoferrin polypeptide is a good additive for infant formulas and animal feed or drugs due to its bacteriostatic, cell growth stimulatory or inflammation inhibitory effects.

Lactoferrin polypeptides have been isolated mainly from milk serum. Recently, mass production of polypeptides by genetic engineering have been attempted. Ward and Piddington have produced 2 g/l quantity of recombinant lactoferrin in Aspergillus oryzae using a glucoamylase promoter (Ward, P.P. et.al., Biotechnology, 13:498-503 (1995)). Qianwa reported that 1.5-2.0 mg/l of recombinant human lactoferrin was obtained by expressing it in the form of a fusion protein between a yeast invertase and human lactoferrin by using a chelatin promoter in Saccharomyces cerevisiae (Qianwa Liang et.al., J. Agric. Food. Chem. 41:1800-1907 (1989)). It was discussed that the recombinant lactoferrin synthesized from S. cerevisiae had additional sugar units, and the yield was not reproducible. In the case of producing lactoferrin or its antibacterial peptide derivatives by using genetic engineering techniques, expressed lactoferrin or antibacterial peptide could slow down the growth of or even kill the host microorganism. To overcome this problem, it is reported that the antibacterial peptide was expressed in the form of a fusion peptide. In US patent 5571697, antibacterial polypeptide derived from lactoferrin was expressed as a fusion protein in Aspergillus.

BRIEF SUMMARY OF THE INVENTION The present invention provides a method to mass-produce lactoferrin polypeptide from microorganisms.

The present invention provides a method to mass-produce lactoferrin polypeptide alone from microorganisms.

The present invention provides a novel germ strain, which is resistant against lactoferrin polypeptide.

The present invention provides a germ strain that produces lactoferrin polypeptide.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a photograph showing the resistance of microorganisms against lactoferrin polypeptide of the present invention.

Figure 2 is a scheme of the preparation method of an expression vector used in the present invention.

Figure 3 is a photograph showing the resistance of the transformant by expressing human lactoferrin polypeptide of the present invention against lactoferrin polypeptide.

Figure 4A-4F are photographs showing the resistance of the transformant by expressing Korean cow lactoferrin polypeptide of the present invention against lactoferrin polypeptide.

DETAILED DESCRIPTION OF THE INVENTION

The present inventors have explored lactoferrin polypeptide resistant germ strains from samples of soybean sauce, soybean paste and wine obtained from Choongchung province, Korea. The inventors also screened and identified superior lactoferrin polypeptide resistant strains.

In the present application lactoferrin polypeptides means lactoferrin or all of the antibacterial peptides or polypeptides derived from lactoferrin unless otherwise specified. The origin of the lactoferrin is not limited, and the lactoferrin can be from human, cow, pig or other mammals. Since the microorganism of the present invention is extremely resistant against lactoferrin polypeptide, the lactoferrin polypeptide can be produced as a fusion protein or a peptide itself by the microorganism of the present invention.

Also the microorganism of the present invention can be used in mass- producing not only lactoferrin polypeptide but also other antibacterial peptides that are difficult to mass-produce due to its activity to slow down the growth of or to kill the host cells.

The present invention also relates to the method of mass-producing the lactoferrin polypeptides from microorganisms composed of the following steps: preparing a plasmid vector composed of a promoter sequence active in a yeast cell and a sequence that is connected to the promoter and which codes the lactoferrin polypeptide;

transforming the lactoferrin polypeptide resistant yeast with the above

vector; and culturing the transformed yeast.

The yeast cell of the present invention can be selected from

Saccharomyces, Aspergillus, Pichia, and Candida, and preferably Pichia genus

cells.

In the preparation method of the present invention, the sequence coding

lactoferrin polypeptide can be a sequence coding a fusion polypeptide fused with

another peptide or a sequence coding additional amino acid residues in addition to

the lactoferrin polypeptide or a sequence coding the lactoferrin polypeptide only. An

altered sequence can also be used if it codes the identical polypeptide as the

lactoferrin polypeptides.

The present invention is also directed to the Pichia pastoris cell that

contains the vector having the lactoferrin polypeptide genes.

The restriction enzymes and other enzymes used in the Examples of the

present invention were obtained from Boehringer Mannheim Biochemical Company.

Oligonucleotide primer was obtained from Invitrogen, and the components of the

media such as amino acids, yeast nitrogen base (YNB), yeast extracts, peptone

and glucose were obtained from Difco. Human lactoferrin and other reagents

used in the protein electrophoresis were obtained from Sigma.

E. coll Top10F' and Pichia pastoris SJW-28 of the present invention were used in the transformation.

The compositions of the media in the present invention are as follows.

YM medium: yeast extracts 0.3 %, malt extract 0.3 %, peptone 0.5 %, dextrose 1 %, agar 2 %.

YM-L medium: the medium that contains 1 mg of lactoferrin-pepsin hydrolysis product in 1 ml YM medium.

YPD liquid medium: yeast extract 1 %, peptone 2 %, dextrose 2 %, The invention will be further illustrated by the following examples, but the invention is not limited to the examples given.

EXAMPLE 1. Selection of the host microorganism that is resistant against lactoferrin polypeptide The lactoferrin polypeptide resistant microorganisms were selected primarily by smearing wine and soybean sauce samples in YM-L medium.

Secondary verification of the antibacterial activity against lactoferrin polypeptide was performed by following the method by H. Wakabayashi (Hiroyuki Wakabayashi, et.al., J. Food Protection, 55(4):280-240.6 (1992)). In a medium containing the primarily selected germs, a paper disk that was immersed in the lactoferrin hydrolysis product that was obtained by treating 1 ml of lactoferrin 1 mg/ citrate buffer solution at pH 2 with pepsin (10 unit/ml) at 37 °C for 4 hours was

placed. A formation of a clear zone was observed. The germ strains that had excellent resistance against lactoferrin polypeptide were selected (Figure 1) and named as "SJW-28". The identification procedure using a PI-CHE kit and other microorganism identification methods, based on N.J.W. Kreger-Van Rij. 1987 were used. The yeasts: a taxonomic study third revised and enlarged edition, Elsevier, were used to identify it as P. pastoris or related germ strains. This cell line was deposited at the Korean Collection of Type Cultures (KCTC) in Korea Research Institute of Bioscience and Biotechnology located at Yusung-ku Eoeun-dong, Taejon, Korea on July 8, 1998, and the number KCTC0500BP was given. Table 1

Table 2

EXAMPLE 2. Subcloning of human lactoferrin polypeptide

The expression vector containing the lactoferrin polypeptide genes was prepared as described in Figure 2. Primers A (forward; 35mer) and B (backward; 30 mer) identified below were used to obtain a lactoferrin polypeptide gene by performing polymerase chain reaction (PCR) with pRL100 (North Dakota State University, Dept. of Biochemistry, Molecular Biology Laboratory) containing a human lactoferrin gene. The primers A and B were designed to amplify the sequence containing disulfide bond of cysteine in the human lactoferrin base sequence. Primer A 5'-GGAAGCTTAAAAGATACGTAAAATGCTTCCAATGG-3' Hind\\\ SnaB\

Primer B δ'-GGGAATTCTCAAAATCTCTTTATGCAGCTG EcoRI Lactoferrin polypeptide gene and amino acid sequences derived from pRL100

AAA GC TTC CAA TGG CAA AGG AAT ATG AGA AAA GTG CGT K C F Q W Q R N M R K V R

GGC CCT CCT GTC AGC GC ATA AAG AGA G P P V S C I K R

Finally amplified lactoferrin polypeptide gene and amino acid sequences

GTA AAA TGC TTC CAA TGG CAA AGG AAT ATG AGA AAA GTG V K C F Q W Q R N M R K V

CGT CCT CCT CCT GTC AGC R P P P V S

Derived from Primer A

TGC ATA AAG AGA TTT C I K R F Derived from Primer B

Expression vector pPIC9-LFP was obtained by treating the amplified lactoferrin polypeptide gene and pPIC9(lnvitrogen) with SnaB\ and EcoRI and by connecting them. pPIC9-LFP was transformed in E. coli, Top 10F'. The transformed colony was selected by obtaining the growing colonies after smearing in an ampicillin containing medium. EXAMPLE 3. Production of human lactoferrin polypeptide using SJW-28. pPIC-LFP was transformed in SJW-28 by electrophoration using the method by Chang et.al. (Chang et.al., Guide to electrophoration and electrofusion. Academic Press, p501 (1992)). In other words, after SJW-28 was cultured in YPD liquid medium to OD₆₀₀ 1.3-1.5, pellet was obtained by centrifuging 500 ml of the culture medium. After the pellet was resuspended in 100 ml of YPD, it was treated with 20 mM and 25 mM of HEPES (N-[2-hydroxyethyl]piperazine-N'[2- ethanesulfonic acid], pH 8.0) and dithiothreitol, respectively and reacted at 30 °C

for 15 minutes. After the solution was dissolved in 0.5 ml of 1 M sorbitol, 40 μl was

taken and added into a pre-chilled gap cuvette with 100 mg of pPIC9-LFP digested by Sa/I. After the mixture was reacted for 5 minutes in ice, electrophoration was performed at 1500 V and 25 mA. Immediately after the electrophoration, 750 μl of

cold 1 M sorbitol was added, and 100 μl of the mixture was smeared in YM medium.

Genomic DNA of the transformant that grows in YM medium was purified to finally select the strain in which lactoferrin polypeptide gene had been inserted, by performing PCR using the above mentioned primers A and B.

Lactoferrin polypeptide gene and amino acid sequences produced by the transformant

GAG GCT GAA GCT TAA GTA AAA TGC TTC CAA TGG CAA AGG E A E A Y V K C F Q W Q R

AAT ATG AGA AAA GTG CGT GGC CCT CCT N M R K V R G P P Derived from pPIC9, Derived from Primer A GTC AGC TGC ATA AAG AGA TTT V S C I K R F

Derived from Primer B

After finally selecting the transformant it was cultured to OD₆₀₀ 1.3-1.5 in

PD medium, a paper disc that was immersed in the medium containing the transformant was placed on a LB agar medium evenly smeared with E.coli JB 109. Antibacterial activity was identified by observing the formation of the clear zone

(Figure 3; M: SJW-28 transformed with pPIC9, 1 : transformant, 2: transformant).

EXAMPLE 4. Production of Korean cow lactoferrin polypeptide using SJW-28.

The following primers were prepared based on the known lactoferrin amino acid sequence. Forward primer 5' - GGCTCGAGCTTGGACTGTGTCTGGCT - 3'

Xho l

Backward primer 5' - GGCTCGAG7 4ATCMAGGGTCACAGCATC - 3'

Xho l

A DNA fragment of about 220 bp containing a part of the Korean cow lactoferrin polypeptide was obtained by PCR using the Korean cow lactoferrin cDNA as a template. Expression vector pKLFC was obtained by treating the

Korean cow lactoferrin polypeptide gene and pPIC9(lnvitrogen) with Xho\, respectively and by connecting them. pKLFC was transformed in E. coli, Top 10F'.

The transformed colony was selected by obtaining the growing colonies after smearing in an ampicillin containing medium. A plasmid containing the Korean cow lactoferrin polypeptide forwardly was selected by the treatment of restriction enzyme and PCR. The plasmid containing the Korean cow lactoferrin polypeptide in forward direction was isolated and this was found to have nearly similar sequence to a part of the cow lactoferrin gene which as reported. The DNA sequences of the Korean cow lactoferrin polypeptide and the DNA sequences of the cow lactoferrin polypeptide were compared as below. The portions of different bases were marked with underline.

Cow: CTTGGACTGTGTCTGGCTGCCCCGAGGAAAAACGTTCGATG

Korean Cow: CTTGGACTGTGTCTGGCTGCCCCGAGGAAAAACGTTCGATG

Cow: GTGTACCATCTCCCAACCCGAGTGGTTCAAATGCCGCCGCC

Korean Cow: GTGTACCATCTCCCGACCCGAGTGGTTCAAATGCCGCCGCC Cow: GATGGCAGTGGAGGATGAAGAAGCTGGGTGCTCCCTCTATC

Korean Cow: GATGGCAGTGGAGGATGAAGAAGCTGGGTGCTCCCTCTATC

Cow: ACCTGTGTGAGGAGGGCCTTTGCCTTGGAATGTATCCGGGC

Korean Cow: ACCTGTGTGAGGAGGGCCTTTGCCTTGGAATGTATCCGGGC

Cow: ATCGCGGAGAAAAAGGCGGATGCTGTGACCCTGGATGGT Korean cow: ATCGCGGAGAAAAAGGCGGATGCTGTGACCCTTGATTAA

(stop codon)

As described in Example 3, a plasmid containing the DNA of the Korean cow lactoferrin polypeptide in forward direction was transformed in Pichia pastoris SJW-28 by electrophoration. The strain inserted with the lactoferrin polypeptide gene was finally selected with PCR by using the aforementioned forward primer and backward primer.

YPD medium, a paper disc that was immersed in the medium containing the transformant was placed on a LB agar medium evenly smeared with the test strains. Antibacterial activity was identified by observing the formation of the clear zone. The results were represented in Figure 4A - 4F wherein the antibacterial activities were tested against the following microorganisms: Figure 4A: Streptococcus mutans KCTC 3065, Figure 4B: Psudomonas aerogenosa KCTC 2004, Figure 4C: Enterobacter aerogenos KCTC 2190, Figure 4D: Eschehchia coli JM109 KCTC 2427, Figure 4E: Salmonella, Figure 4F: Escherichia coli o157:H7. (Figure 4A - 4F: C: SJW-28; 3: transformant; 6: transformant).

It is possible to mass produce the lactoferrin polypeptide and other antibacterial peptides by the present invention.

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1

: Samyang Genex Corp.

#263 Yeongji-dong, Chongno-ku, Seoul 110-725, Republic of Korea

I. IDENTIFICAΉON OF THE MICROORGANISM

Identification reference given by the Accession number given by the DEPOSITOR: INTERNATIONAL DEPOSITARY AUTHORITY:

Pichia pastoris SJW-28

KCTC 0500BP

II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

[ x ] a scientific description

[ ] a proposed taxonomic designation

(Mark with a cross where applicable) in. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above, which was received by it on July 08 1998.

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority on and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Korea Research Institute of Signature(s) of person(s) having the power to Bioscience and Biotechnology represent the International Depositary Korean Collection for Type Cultures Authority or of authorized offιcial(s):

Address: KCTC, KRIBB

#52, Oun-dong, Yusόng-ku, Taejon 305-333, Republic of Korea

Claims

What is claimed is:

1. Pichia pastoris KCTC 0500BP.

2. A preparation method of lactoferrin polypeptides from microorganisms comprises of the following steps; preparing a plasmid vector composed of a promoter sequence active in a yeast cell and a sequence that is connected to the promoter and which codes the lactoferrin polypeptides; transforming the yeast which is resistant against lactoferrin polypeptides with above vector; and culturing the transformed yeast.

3. The method according to Claim 2 wherein the yeast cell is Pichia cell.

4. The method according to Claim 3 wherein the Pichia cell is KCTC 0500BP.

5. The method according to Claim 2 wherein the sequence coding lactoferrin polypeptides is a sequence coding in the form of fusion peptide of lactoferrin or lactoferrin polypeptides.

6. A method according to the Claim 2 wherein the sequence coding lactoferrin polypeptides is a sequence coding lactoferrin polypeptides alone.